1-(bromomethyl)-4-(isopropylsulfonyl)benzene | 942199-51-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(bromomethyl)-4-(isopropylsulfonyl)benzene
• 英文别名: 1-bromomethyl-4-(propane-2-sulfonyl)-benzene；1-(Bromomethyl)-4-(propane-2-sulfonyl)benzene；1-(bromomethyl)-4-propan-2-ylsulfonylbenzene
• CAS: 942199-51-1
• 化学式: C₁₀H₁₃BrO₂S
• 分子量: 277.182
• InChiKey: KLIADIYQTGCHJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(bromomethyl)-4-(isopropylsulfonyl)benzene 在 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 2.5h， 生成 2-(1-(4-(isopropylsulfonyl)benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid
  参考文献：
  名称：

  Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma

  摘要：

  Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-ypacetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.

  DOI：

  10.1021/acsmedchemlett.7b00157
• 作为产物：
  描述：

  (4-(isopropylsulfonyl)phenyl)methanol 在 三溴化磷 作用下， 以 乙醚 为溶剂， 反应 16.0h， 以77%的产率得到1-(bromomethyl)-4-(isopropylsulfonyl)benzene
  参考文献：
  名称：

  Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma

  摘要：

  Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-ypacetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved potency on human eosinophils and Th2 cells, together with a longer receptor residence time, and is currently in clinical trials for severe asthma.

  DOI：

  10.1021/acsmedchemlett.7b00157

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2005123731A2

  公开（公告）日：2005-12-29

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了公式（I）的化合物，以自由形式或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，以及制备它们的过程，和它们作为药物的用途。
• Pyrrolopyridine Derivatives And Their Use As Crth2 Antagonists
  申请人：Bala Kamlesh Jagdis

  公开号：US20080114022A1

  公开（公告）日：2008-05-15

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了公式（I）的化合物，以自由或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，制备它们的过程以及它们作为药物的用途。
• Organic Compounds
  申请人：Sandham David Andrew

  公开号：US20080312230A1

  公开（公告）日：2008-12-18

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R 1 , R 2 R 3 R 4 , R 5 , R 6 , Q, X, m, n, and p are as described in the specification, on process for preparing them, and their use in the manufacture of a medicament for the treatment of neuropathic pain.

  根据本发明，提供了具有式（I）的化合物，以自由或盐形式存在，其中R1，R2R3R4，R5，R6，Q，X，m，n和p如规范中所述，以及制备它们的过程，并将它们用于制造用于治疗神经病性疼痛的药物。
• Organic compounds
  申请人：Bala Kamlesh Jagdis

  公开号：US20100210610A1

  公开（公告）日：2010-08-19

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明提供了式（I）的化合物，以自由形式或盐形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如说明书中所述，以及制备它们的过程和它们作为药物的用途。
• Pyrrolopyridine derivatives and their use as CRTH2 antagonists
  申请人：Bala Kamlesh Jagdis

  公开号：US08455645B2

  公开（公告）日：2013-06-04

  There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

  根据本发明，提供了式（I）的化合物，以自由或盐的形式提供，其中R1、R2、R3、R4、R5、R6、Q、W、X、m、n和p如规范中所述，制备它们的过程以及它们作为药物的用途。